NASDAQ, CERS - Cerus Corp
We are a biomedical products company focused on commercializing the INTERCEPT
Blood System to enhance blood safety. The INTERCEPT system is designed to
inactivate blood-borne pathogens in donated blood components intended for
transfusion. The company currently markets the INTERCEPT system for both
platelets and plasma in Europe and the Middle East. We are also pursuing
regulatory approvals in the United States and other countries. The INTERCEPT red
blood cell system is currently in clinical development.
We have worldwide commercialization rights for the INTERCEPT Blood System for
platelets, plasma and red blood cells, excluding certain countries in Asia where
we have licensed commercialization rights to the platelet and plasma systems to
BioOne Corporation, or BioOne. We previously collaborated with subsidiaries of
Baxter International Inc., or Baxter, in the development and commercialization
of the INTERCEPT Blood System. ...
Read SEC Filing on NASDAQ.com »